Kit for predicting immunotherapy effect

Abstract

The invention discloses a kit for predicting an immunotherapy effect, and particularly relates to the technical field of kits. The kit comprises a shading layer, wherein the shading layer is internally provided with a kit. According to the invention, the target cells in the peripheral blood mononuclear cells are directly detected, so that the tumor tissues in the body of a patient do not need to be collected through a special operation, the adverse risk brought to the patient by adopting a surgical collection method is avoided, the whole operation process is relatively convenient and rapid, and the large pain brought to the patient during the surgical collection process can be effectively reduced, so that the kit is easy to be accepted by the patient and the family members thereof. The blocking agent blocks the PD-1 and TCR stimulation so as to cause the reversal of the resistance to the PD-1, such that the drug resistance of the PD-1 treatment can be enhanced, and the PD-1 treatment is enabled to show a good treatment effect. Therefore, the method disclosed by the invention has a relatively wide market, and the predictive biomarker disclosed by the invention can benefit a patient receiving PD-1 treatment.

Description

technical field [0001] The invention relates to the technical field of kits, more specifically, the invention relates to a kit for predicting the effect of immunotherapy. Background technique [0002] In the field of cancer treatment, immunotherapy is one of the feasible medical methods to overcome the worldwide problem of cancer in the future. Immunotherapy refers to a series of drugs that can strengthen the immune system, induce or restore cytotoxic T cells or other immune effector cells. Function, to achieve the process of eliminating tumor cells, among them, PD-1 antibody is an immune checkpoint inhibitor, as a new drug for tumor immunotherapy, it has become the most important breakthrough in cancer treatment. [0003] PD-1 immune checkpoint inhibitor is a new type of treatment, which is leading a new revolution in cancer treatment. With the arrival of two PD-1 monoclonal antibodies from foreign pharmaceutical companies in the mainland market, BEST Odivo (O drug) of My ...

AI Technical Summary

Problems solved by technology

[0003] PD-1 immune checkpoint inhibitor is a new type of treatment, which is leading a new revolution in cancer treatment. With the arrival of two PD-1 monoclonal antibodies from foreign pharmaceutical companies in the mainland market, BEST Odivo (O drug) of My Squibb and Merck’s Keyrad (K drug), PD-1 immunotherapy has become more and more accepted by people and has become a popular cancer treatment method. However, the immunotherapy presented The effect is indeed different. Some PD-1 immunotherapy has not achieved good therapeutic effect, while others have the opposite effect, indicating that PD-1 immunotherapy can only show good curative effect in some patients. Accurately finding these effective patients is a difficult problem in current clinical treatment. There is no method on the market that can predict the therapeutic effect of patients, and the kits in the prior art generally require the user to use a recording tool in order to facilitate identification It is cumbersome to label it and then paste it on the surface of the kit, and it is necessary to purchase additional writing and pasting tools for use

Images